Taking Low-Dose Naloxone
Naloxone is a medication that was approved by the FDA in 1984 to treat opioid addiction; the amount of naloxone given for opioid addiction is high compared to the amount given for chronic pain. The effect on the body of high doses versus low doses of naloxone is drastically different. When given at a low dose (usually 1/10 of the dosage given for opioid addiction), this medication is effective in providing relief for chronic pain. The average dosage given in clinical trials (studying the effectiveness of the drug for chronic pain) is 4.5 mg.
Low-dose naloxone (LDN) operates as an anti-inflammatory agent in the central nervous system. It is a valuable option for those suffering from fibromyalgia, multiple sclerosis, complex regional pain syndrome (CRPS), Crohn's disease and cancer. Although low-dose naloxone has yet to be approved by the FDA, it has proven very effective in clinical studies. During a published clinical study, 30 fibromyalgia sufferers were given a 4.5 mg oral dosage of LDN at night time, and 57% of participants reported a significant reduction of pain.
Not only does naloxone reduce pain levels, but it also can aid with fatigue, stress, sleep issues, gastrointestinal problems, and headaches. The most common side-effects have been vivid dreams and difficulty sleeping. LDN is inexpensive and usually well tolerated.
Endorphin secretions play an important part in the immune system. Findings in LDN- effectiveness-for-chronic-pain clinical trials demonstrate that between 2:00 a.m. and 4:00 a.m. blood level endorphins, which play a vital part in immune system function, are increased. Many participants in these clinical trials have a deficiency of endorphins. Restoration of the body's normal endorphin production is the major therapeutic action of LDN for chronic-pain patients. Even though LDN is still in the experimental stage, it is proving advantageous as a viable treatment option for chronic pain.